Gluomni-M2: Complete Guide to Glimepiride and Metformin

Gluomni-M2 is a prescription medicine marketed in India by EMK Omni Pharma, Mysuru, Karnataka. Each uncoated bilayer tablet contains Glimepiride IP 2 mg and Metformin Hydrochloride IP 500 mg as prolonged release, along with approved excipients. It sits in the Diabetes Care category and is supplied in a pack of 10 X 10 tablets.

Doctors prescribe Gluomni-M2 for adults with type 2 diabetes whose blood glucose is not well controlled by diet and exercise alone, or by a single oral medicine. It is not used for type 1 diabetes and it is not something anyone should start without a consultation. The pack carries a Schedule H warning, which means it is not to be sold by retail without the prescription of a registered medical practitioner. EMK Omni Pharma markets the brand and the tablets are manufactured on its behalf at GMP certified units.

Type 2 diabetes usually involves two problems at the same time. The pancreas does not release enough insulin, and muscle, fat and liver cells respond poorly to the insulin that is there. Gluomni-M2 approaches both sides with two molecules held in separate layers of one tablet.

Glimepiride belongs to the sulfonylurea group. It acts on the beta cells of the pancreas and prompts them to release more insulin, which brings blood glucose down. Metformin belongs to the biguanide group. It mainly reduces the amount of glucose the liver produces and helps muscle tissue take up glucose more readily, so the body uses its own insulin better. The prolonged release layer lets metformin be delivered gradually rather than all at once, which many patients find easier on the stomach. Used together under medical supervision, the two may help improve both fasting and after meal readings.

The bilayer format keeps the immediate acting glimepiride layer and the prolonged release metformin layer distinct, so each molecule is released in the manner it is designed for. The MRP and batch details are printed on the carton and on the blister foil.

Treatment for type 2 diabetes in India usually starts with a diet plan, physical activity and metformin. When blood glucose and HbA1c stay above the target the doctor has set, a second molecule is commonly added. A sulfonylurea such as glimepiride is one of the most widely used additions because it acts on insulin release and is available at a modest cost.

A fixed dose combination such as Gluomni-M2 folds that step into a single tablet. Taking fewer tablets often makes it easier to stay regular with treatment, which matters a great deal in a condition managed over many years. The 2 mg glimepiride content sits in the middle of the usual range, so a doctor may choose it for someone already stabilised on a lower strength who now needs a step up.

The other articles in this cluster go into detail on single questions. One explains what Gluomni-M2 is used for and what it does not do. Another describes how the tablet is generally taken, including food, timing and missed dose principles. A third covers side effects, from common stomach upset to the warning signs of low blood sugar.

There is a page on precautions and drug interactions, a storage guide written for Indian heat and monsoon humidity, and a patient question and answer page. Further articles explain the glimepiride and metformin molecules and why combination tablets exist, describe type 2 diabetes as a condition, compare Gluomni-M2 with the other diabetes brands in the EMK Omni Pharma range, and give dispensing and counselling notes for doctors, pharmacists and distributors.

Tell your doctor before starting Gluomni-M2 if you have kidney or liver trouble, heart failure, a history of frequent low blood sugar, or if you are pregnant, planning a pregnancy or breastfeeding. Share a full list of everything else you take, including ayurvedic preparations, supplements and over the counter painkillers.

During treatment, contact your doctor promptly if you have repeated episodes of shakiness, sweating and confusion, persistent vomiting, unusual muscle pain with fast breathing, or if you become unwell with fever, diarrhoea or dehydration. Your doctor decides the dose, the timing and the duration, and may revise it after reviewing your blood reports. This article is for general information only and is not a substitute for advice from a registered medical practitioner.